N/A N=204 Safety & Prevention Outcomes Study
Drug Overdose · Opioid-Related Disorders
Primary: Overdose Risk Behavior — -1.54; -0.51 Scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=76 Evaluation of a Computerized Opioid Overdose Prevention Program
Computer + Fluency · Computer Only · Treatment as Usual
Primary: Knowledge Gain — 30.6; 30.5; 27.56; 40.7 units on a scale
N/A N=43 Preventing Overdose Using Information and Data From the Environment
Opioid Overdose · Drug Overdose
Primary: Cumulative Incidence of Accidental Fatal and Non-Fatal Drug Overdoses — 43.5; 37.1 Overdoses per 10,000 residents
N/A N=509 The Rhode Island Prescription and Illicit Drug Study
Opioid Overdose · Drug Overdose
Primary: Number of People Identified Has Having One or More Overdose Among RAPIDS Trial Participants — 48; 36 Participants
Phase 4 N=256 Project OOPEN: Opioid Overdose Prevention, Education and Intervention
Opioid Overdose
Primary: Rate of Fatal Opioid Overdose — 2; 6 Participants
N/A N=190 Opioid Prescribing After Cesarean Delivery
Surgery · Opioid Use
Primary: Unused Opioids — 5; 10 oxycodone 5mg tablets
N/A N=2,272 Drug Use Investigation of Jzoloft.
Panic Disorder · Depression
Primary: Number of Participants of Treatment Related Adverse Events (TRAEs) — 263 participants
N/A N=395 Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Use Disorder
Opiate Antagonist Overdose · Opioid-Related Disorders
Primary: To Measure the Association of Take-home Naloxone With Overdose Reversals Performed by Patients With Opioid Use Disorder Enrolled in an Opioid Treatment Program — 73; 263…
Phase 4 N=319 Increasing Naloxone Access for Persons Who Use Opioids
Naloxone
Primary: The Number of Participants That Completed the Training in 6 Months — 55; 56; 10; 9 Participants
Phase 1 N=11 Prescription Medication Interactions
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
N/A N=348 Emergency Department (ED) Drug Interaction in Emergency Department Patients
Drug Interactions
Primary: Difference in Clinically Significant Visual Analogue Scale for Pain and Nausea Change Between CYP2D6 Users and Non-users — 7.4; 10.9; -14.0 millimeters
N/A N=299 Primary Care Intervention to Reduce Prescription Opioid Overdoses
Pain · Drug Overdose · Opioid Use Disorders
Primary: Overdose Risk Behaviors — 1.31; 1.21; 1.45; 1.25 score on a scale
N/A N=60 Smartphone Intervention for Overdose and COVID-19
Substance Use Disorders · Overdose · COVID-19
Primary: Content Completion Rate Assessed as Number of Participants Who Completed at Least 6 of the 12 Weeks of the Intervention — 40 Participants
N/A N=150 Peer Intervention to Link Overdose Survivors to Treatment (PILOT)
Opioid Overdose
Primary: Number of Self-reported Overdose Risk Behaviors at 180 Days (6 Months) After Index ED Admission — 4.5; 5.6 units on a scale — p=0.399
N/A N=1,804 A High School Program for Preventing Prescription Drug Misuse
Prescription Drug Abuse · Substance Abuse · Substance Use (Drugs, Alcohol)
Primary: Prescription Drug Misuse (i.e., Prescription Drug Use Without a Doctor's Prescription) — 1.06; 1.12; 1.11; 1.13 score on a scale
N/A N=1,194 Drug Use Investigation Of Gabapentin
Epilepsies, Partial
Primary: Number of Participants With Treatment-Related Adverse Events Unexpected From Japanese Package Insert — 27 participants
N/A N=105 Preventing Opioid Overdose Mortality in the United States
Opioid Overdose
Primary: Naloxone Coverage (Consistency) — 0.9; 0.4 proportion of participants — p=<0.01
N/A N=851 Behavioral Insights to Encourage Judicious Prescribing of Opioids
Substance-Related Disorders
Primary: Average Change Over Time in Dispensed Narcotics — 347.65; 350.09; 288.36; 318.60 Morphine milligram equivalents — p=<0.05
N/A N=3,939 Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)
Smoking Cessation
Primary: Risk Factors for the Frequency of Treatment Related Adverse Events - Gender. — 377; 336 participants — p=<0.001
N/A N=268 Repeated-dose Behavioral Intervention to Reduce Opioid Overdose
Opioid-Related Disorders · Drug Overdose
Primary: Number of Overdose Events — 0; 0 overdoses
N/A N=19 The Adverse Drug Reaction (ADRe) Profile for Polypharmacy
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
Phase 2 N=14 Non-intrusive Detection of Temporary Neurologic Impairment By Opioids
Healthy
Primary: Oculo-Cognitive Addition Test (OCAT) Completion Time — 57.22; 57.22; 59.56; 58.18 seconds
N/A N=321 Subthreshold Opioid Use Disorder Prevention (STOP) Trial
Opioid-use Disorder
Primary: Days of Risky Opioid Use in Past 180 Days — 12.2; 15.5 days
N/A N=78 Stress, Distress Intolerance, and Drug Dependence
Substance Dependence
Primary: Percentage of Positive Toxicology Swabs for Illicit Substances — 81.3; 79.1; 86.2; 82.3 percentage of positive toxicology screen
N/A N=253 Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program
Opioid Overdose
Primary: Number of Opioid-related Adverse Events — 4.15; 3.24 Events
N/A N=31 Methadone Monitoring for Insights Into Adverse Events
Pain · Opiate Addiction
Primary: Total Methadone Peak Plasma Concentration — 107.3; 315.4; 362.2 ng/mL
N/A N=127 Post-op Crowd Sourcing Health Data Via Text-messaging
Orthopedic Surgery · Opioid Use · Acute Injuries Knee
Primary: Number of Opioid Tablets Taken Within 28 Days — 8.05; 11.55 number of pills taken
N/A N=75 Excess Opioid Disposal Following Orthopedic Foot and Ankle Surgery
Medication Disposal · Behavior
Primary: Number of Participants Who Safely Disposed The Excess Medication — 8; 22 Participants
N/A N=97 User Acceptability of a Device-Based Opioid Overdose Intervention
Opioid Overdose · Opioid-use Disorder · Substance Use Disorders
Primary: Community Need for a Device-based Opioid Overdose Intervention — 69; 22 Participants
N/A N=115 Suicide Prediction and Prevention for People at Risk for Opioid Use Disorder: Supplement to COMPUTE 2.0
Opioid Use · Opioid-use Disorder · Suicide
Primary: Number of Participants With CSSRS Completion on the Same Day or in the 14 Days Following Any Outpatient Visit — 14; 8 Participants